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Abstract 
Inhibition of DNA methyltransferases emerged as a novel treatment strategy in solid tumors. 
Aberrant hypermethylation in promoters of critical tumor suppressor genes created a premise, that 
treatment with hypomethylating agents may lead to restoration of “normal” epigenome and 
produce clinically meaningful therapeutic outcome.  The aim of this review article is to summarize 
the current state of knowledge of DNA methyltransferase inhibitors in the treatment of 
genitourinary malignancies. We performed a literature search of PubMed/Medline, ASCO, ASCO 
GU and AACR libraries on September 17th 2017. Included reports evaluated pre-clinical and 
clinical studies assessing the role of DNA methyltransferase inhibitors in genitourinary 
malignancies. The efficacy of DNA methyltransferase inhibitors in genitourinary malignancies 
was reported in number of studies and suggested the role of DNA hypomethylation in overcoming 





Increasing knowledge about epigenetic landscape in cancer leads to discovery of promising novel 
drugs. 
 
Evidence from pre-clinical and clinical studies suggests that DNA methyltransferase inhibitors 
provide anticancer activity in number of tumors.  
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DNA methyltransferase inhibitors deliver cytotoxic and chemoresistance overcoming effects in 




The conventional paradigm of phenotype manifesting as a sole result of the information 
encoded in the DNA experienced radical shift over the recent years. Epigenetic changes represent 
series of mechanisms interfering with the DNA and its function without altering the sequence in 
coding genes. Both, genetic and epigenetic aberrations cooperate to produce conformational 
changes in chromatin and biochemically alter gene promoters. Such regulation induces or represses 
the transcriptional gene activity and may ultimately lead to carcinogenesis 1, 2. 
Recent studies indicate that epigenetic silencing may be as important as DNA mutations in 
tumorigenesis and treatment resistance 3. While mutations represent an irreversible change in the 
DNA sequence, epigenetic silencing is a reversible process. Known modifications with ability to 
influence the gene expression without altering the DNA sequence include DNA methylation, 
histone modifications, nucleosome remodeling induced by ATPases, and regulation via non-
coding RNAs3-6. This review will summarize the current state of pre-clinical and clinical 
knowledge in targeting DNA methyltransferases, a key messengers for DNA methylation, in 
genitourinary cancer. 
 
2. Literature search 
We performed a literature search of the PubMed/Medline database, and meeting libraries of 
American Society of Clinical Oncology (ASCO), ASCO Genitourinary Cancers Symposium and 
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American Association for Cancer Research (AACR) for publications with the terms “epigenetics”, 
“DNMT”, “DNMTi” “genitourinary”,  “testicular cancer”, “germ-cell tumors”, “bladder cancer”, 
“renal cell carcinoma”, “prostate cancer”, “penile cancer”, “azacitidine”, “decitabine”, 
“guadecitabine”, “zebularine”, “non-nucleoside”. Combinations of these key words were used for 
comprehensive search as outlined in Figure 1. The search of literature was performed on 
September 15th 2017. Original full-text articles published in English were reviewed and the 
reference lists of key articles were further evaluated. We did not limit our search by the years of 
publication. Our search was conducted according to the Preferred Reporting Items for Systematic 
Review and Meta-analysis (PRISMA) statement. Identified reports were reviewed according to 
the Consolidated Standards of Reporting Trials (CONSORT) criteria. The search resulted in 
overall 4, 152 publications. One hundred and eleven publications were selected for inclusion in 
our review article [88 original papers (79%) and 23 (21%) review articles]. The literature search 
and the inclusion and exclusion criteria are summarized in Figure 1 and Table 1.  
 
3. DNA Methylation 
A covalent addition of methyl groups (-CH3) to the carbon-5 position of cytosine 
represents a non-coding modification of DNA – a methylation 7. DNA methylation at the 5′-CG-
3′ sequence (also CpG dinucleotide) is a unique, heritable mechanism for regulation of gene 
transcription. Hypermethylation generally acts as gene silencer by downregulating the 
transcription of CpG-rich promoter regions (CpG islands) of tumor suppressors 8. 5-
methylcytosine may undergo a spontaneous deamination to thymine allowing for changes in the 
chromatin structure. This represents a change in DNA sequence and creates a significant restraint 
to initiate a transcriptional activity. DNA methylation may be found in distinct locations that may 
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further influence gene expression and results in different biological phenotypes. Promoter region 
methylation is a repressive mark, while the gene body methylation is usually associated with active 
gene expression 9, 10. DNA hypermethylation in the promoter region of tumor suppressor genes in 
human cancer may represent one of the most important mechanisms in cancer development 11. 
DNA methylation was discovered to be present also in context of non-CpG (CpA, CpT, CpC). 
Non-CpG methylation coexists with CpG methylation, but the exact role is not clear. Evidence 
suggests an involvement in gene expression when non-CpG methylation is found in promoter 
regions 12. Unlike CpG methylation, non-CpG methylation is asymmetrical and thus the same 
methylation pattern after each cell division cannot be maintained 13. As a result, non-CpG 
methylation is decreased in rapidly proliferating tissues suggesting a potential role in 
carcinogenesis and pluripotency 14, 15. 
The current discoveries have identified significance of enzymatic activity of three DNA 
methyltransferases (DNMTs): DNMT1, DNMT3A, and DNMT3B. The role of DNMT1 is to 
maintain the existing methylation patterns, while DNMT3A and DNMT3B are responsible for de 
novo methylation16.  
 
4. Proposed mechanism of action of DNA methyltransferase inhibitors (DNMTis) in solid 
tumors 
In-depth understanding of the mechanisms underlying the effects of DNMTis is virtually non-
existent. Thus, hypotheses and emerging evidence are outlined in this review article in attempt to 
summarize the current state of knowledge. A well-proven fact that DNMTis are responsible for 
global hypomethylation resulting in (re)expression of certain tumor suppressor genes offers a 
superficial knowledge on how DNMTis deliver their effect 17, 18. On the other hand, global 
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hypomethylation in tumors was linked with aberrant activation of cancer germ-line oncogenes that 
promote cell proliferation, angiogenesis and metastasis 19. It is unclear, whether the intra-tumoral 
hypomethylation activating oncogenes can be overcome by treatment effects of DNMTis which 
alter the whole body methylome. Non-specificity of treatment with DNMTis may raise doubts 
about the safety of drugs with the potential to induce re-expression of tumor-suppressor genes as 
well as oncogenes. Available data from a phase II clinical trial in ovarian cancer did not show any 
secondary malignancies in patients treated with decitabine for 2-30 months 20. Primary target 
population for clinical trials evaluating the efficacy of these novel agents are patients with 
refractory solid tumors pretreated with conventional treatments. Described evidence suggests that 
survival benefit of treatment with DNMTis in this patient population may outweigh the risk of 
potential secondary malignancies. The most common toxicities are nausea, constipation, allergic 
reactions and bone marrow suppression. Grade 3-4 neutropenia and thrombocytopenia were seen 
in 22% and 11% of patients respectively 20.   
Most of the initial clinical trials using a single agent DNMTi to treat solid tumors were 
unsuccessful in improving outcomes.  DNMTis were used at high doses with the intent to deliver 
a non-specific cytotoxic effect, however, the delivery at low doses are optimized to inhibit DNA 
methylation 20-22. More recently, trials are testing whether DNMTis could sensitize refractory 
tumors to chemotherapy and whether they can improve immune response and boost immune 
therapy.  
4.1 DNMTis to overcome chemo-resistance 
Multiple hypotheses are proposed to explain the role of DNMTis in overcoming resistance to 
chemotherapy, specifically the DNA targeted drugs (DTDs). Lethal DNA damage is the main 
mechanism of cell death induced by platinum compounds and doxorubicin 23. Cisplatin induces 
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DNA breaks by creating inter-strand adducts. Doxorubicin also creates DNA damage after being 
incorporated into DNA. DNMTis may potentiate the DNA damage induced by cisplatin and 
doxorubicin by increasing the accessibility of these drugs through loosening chromatin globally, 
which is required for DTD incorporation and DNA damage 24. Furthermore, epigenetic synergy of 
decitabine and platinum agents, but no other cytotoxic drugs, was observed by Qin et al.  in colon 
cancer cell line. Treating the cell line with 16 cytotoxic drugs including platinum agents did not 
result in activation of hypermethylated cytomegalovirus promoter. However, the addition of 
platinum compounds achieved a striking synergy in activating the promoter. Experiments also 
resulted into significantly better reactivation of hypermethylated tumor suppressor genes (MHLM1 
and PDLIM4) with the combination of decitabine and carboplatin, compared to each drug alone, 
therefore offering evidence that platinum resistance can be overcome with the addition of 
decitabine 18  
 
4.2 DNA methyltransferase (DNMT) inhibitors and immune responses 
DNMTis have potency to reactivate the silenced tumor suppressor genes by DNMT 
inhibition, and are capable of upregulating the genes encoding MHC I molecules, tumor antigens 
25-27 and interferon (IFN) response proteins 28. Decitabine upregulated chemokine expression in 
vitro in ovarian tumor cell and increased the number of NK and CD8+ cells in malignant ascites 
in an orthotopic mouse model 29. 
Recent reports suggest immune modulation as a possible mechanism of action for azacitidine. The 
expression of endogenous retroviruses (ERVs) is silenced by DNA methylation 30, 31, and treatment 
with low doses of azacitidine reactivated ERVs in ovarian and colon cancer cells 32, 33. While most 
ERVs have lost the ability to mature and infect other cells, they can still expand within their host 
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genome 27, 34. Upon the expression of ERV, a double-strand RNA (dsRNA) that is constructed 
plays a role in creating of a type I IFN response 32, 33. As a result, azacitidine may induce tumor 
cells to mimic virally infected cells, resulting in an antitumor immune response 35. Several clinical 
trials with azacitidine or guadecitabine in combination with immune checkpoint inhibitors are 
ongoing in various solid tumors.  
 
5. DNA methyltransferase inhibitors (DNMTis) and their mechanism of action 
Historical pre-clinical and clinical studies assessed 5-azacitidine (azacitidine) and 5-aza-
2′deoxycytidine (decitabine) that were among the first agents efficient in downregulating the DNA 
methylation. Azacitidine and decitabine act as inhibitors of DNMTs and are now referred to as 
“first generation DNMTis” preceding a “second generation DNMTis” guadecitabine (2´-deoxy-5-
azacytidylyl-(3´-5´)-2´-deoxyguanosine sodium salt) and zebularine (1-[beta]-D-ribofuranosyl]-
1,2-dihydropyrimidin-2-one). These agents act as cytidine antimetabolite analogues creating 
covalent complexes with DNMTs and DNA. Trapping the DNMTs in this fashion ultimately alters 
their function resulting in downregulation of DNA methylation 36. This covalent trapping, 
however, also induces DNA damage that was suggested in the mutagenic and cytotoxic effects of 
DNMTis 37. Azacitidine and decitabine were therefore initially developed as chemotherapeutic 
agents and were used at cytotoxic doses.  
      First generation DNMTis suffer from fast metabolism induced by hydrolytic cleavage and 
deamination. As a result, their stability in the blood is limited and their use as cytotoxic agents in 
solid cancers proved unsuccessful 38.  The second-generation DNMTis guadecitabine and 
zebularine are stable in the liquid environment and allow for a longer effective half-life 38-40. While 
hypomethylation induced by the first generation DNMTis in in-vitro studies 41-43 brings evidence 
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of effectivity of these agents, downregulating the DNA methylation with guadecitabine in cancer 
xenograft models 44 provided proof that unfavorable pharmacokinetic profile of first generation 
DNMTis can be overcome.  Zebularine was shown to be preferentially incorporated in zebularine-
sensitive tumor cells with specific transcriptomic and epigenomic signature in in-vitro and 
xenograft mouse model experiments with human liver cancer. This shows a promising tool for 
predicting response to this second generation DNMTi 45. Fluorocyclo-pentenylcytosine is another 
novel next generation nucleoside agent with antimetabolic activity that also acts as DNMT1 
inhibitor. Numerous preclinical cell-line and xenograft animal models have shown antitumor 
activity of this drug 46-49.   
Alternative mechanism that reduces CpG island methylation is inhibition of DNMT1 with 
antisense oligonucleotides which are not incorporated into genomic DNA. In-vitro experiments in 
bladder cancer cells have shown that MG88 targeting the 3’-untranslated region of DNMT1 
resulted in suppressed DNMT1 expression, thus allowing for re-expression of tumor suppressor 
gene α-CDKN2A 17. 
Mechanism involved in transport of DNMTis across cell membrane indirectly influence the ability 
of DNMTis to perfom effectively. Human organic cation and nucleoside transporters may both 
mediate intake or efflux of azacitidine, decitabine and zebularine. These transporters, thus, 
contribute to chemoresistance or chemosensitivity to DNMTis in cancer therapy 50.  
Several other non-nucleoside targeting DNMTi agents are procaine 51 N-acetylprocainamide, 
procainamide (perturbing the interactions between the protein and its target sites), hydralazine 
(decreases the expression of DNMT1 and 3A)52, (−)-epigallocatechin-3-gallate (EGCG, a catalytic 
pocket blocker of DNMT1 found in green tea)53, and RG108 (the first rationally designed inhibitor 
of DNMTs)54. Non-nucleoside agents have shown considerably less demethylating activity in 
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bladder and prostate cancer cell lines compared to decitabine 52. Ongoing clinical trials using 
DNMTi agents are summarized in Table 2.  
 
6. Targeting DNMTs in genitourinary cancer  
Following chapters are discussing a current state of evidence in the pre-clinical and clinical use of 
DNMTis in genitourinary malignancies.  
 
6.1 Germ Cell Tumors 
Germ cell tumors (GCTs) have a global DNA hypomethylation that may explain an exceptional 
sensitivity to platinum-based chemotherapy 55-57 resulting from the highest de novo DNA 
methyltransferase expression (DNMT3A/3B) among solid cancers (Figure 2) 58, 59. However, 
numerous promoters in GCT cell lines were discovered to be hypermethylated in non-seminomas60 
and promoter hypermethylation of RASSF1A and HIC1 genes was linked to cisplatin resistance in 
embryonal carcinoma cell lines61. Beyrouthy et al. have shown that overexpression of DNMT3B 
is associated with hypersensitivity to decitabine. Treatment with decitabine resulted in a re-
sensitization of testicular cancer cells to cisplatin.  Furthermore, the demethylation resulted in a 
re-activation of tumor suppressor genes 62. Similar observations were made by Wermann et al., 
who observed an increased sensitivity to cisplatin after treatment with 5-azacitidine in platinum 
resistant GCT cell lines 57. 
We evaluated guadecitabine in vitro and in an in vivo in a mouse model of cisplatin refractory 
GCT and found that testicular cancer cells had exquisite sensitivity to single agent exposure. 
Guadecitabine completely abolished progression and induced complete regression of cisplatin 
resistant testicular cancer xenografts even at doses well below those required to impact somatic 
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solid tumors 22. A phase I study of guadecitabine in combination with cisplatin in refractory GCT 
subjects who relapsed after multiple lines of chemotherapy including high-dose chemotherapy 
(HDCT) is currently ongoing at Indiana University (NCT02429466). Anecdotal evidence from a 
phase II study evaluating hydralazine and magnesium valproate showed a stable disease in 1 
patient with refractory non-seminoma 63. 
 
6.2 Bladder cancer 
Aberrant DNA methylation was initially found to be relevant to carcinogenesis in human bladder 
tumors and cell lines. Later, comprehensive genomic and promoter assessments have shown 
characteristic DNA methylation patterns in bladder cancer 64, 65. Maruyama et al. assessed the 
promoter methylation status of several cancer-related genes including CDH1, RASSF1A, APC, 
CDH13, FHIT, RARβ, GSTP1, p16INK4a, DAPK and MGMT in 98 bladder tumors. High 
methylation frequency in RASSF1A, APC, CDH1, CDH13 and FHIT correlated with poor 
prognostic clinical-pathological features and shorter overall survival 66. Hypermethylation of  
RASF1A, APC and MGMT has been linked to high grade and invasive tumors in 76 patients with 
urothelial bladder cancer  67. In pre-clinical studies, azacitidine inhibited the proliferation of 
bladder cancer cells and arrested cells at the G0/G1 phase. Wang et al. performed in vivo and in 
vitro experiments showing that azacitidine markedly downregulated the expression of 
DNMT3A/3B, reactivated expression of hepaCAM, and inhibited bladder cancer growth in nude 
mice 68. Treatment with demethylating agents decitabine and zebularine (nucleoside analog of 
cytidine) induced a growth inhibition in urothelial bladder cancer and renal cell cancer cells 
resulting in a 17-132% prolongation of cell doubling time 69. A preclinical study evaluating single 
agent azacitidine in 19 dogs with spontaneous urothelial bladder cancer confirmed a 
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myelosupressive, but relatively safe toxicity profile. Partial remission was seen in 22%, stable 
disease in 50% and progressive disease in 22% of dogs evaluable for tumor response 70. Another 
pre-clinical study showed that sensitization of cisplatin resistant bladder cancer cell lines can be 
achieved in vitro by decitabine pre-treatment alone and in combination with the HDAC inhibitor 
vorinostat 71. Chuang et al. conducted a pre-clinical in vivo assessment of single agent decitabine 
and guadecitabine in murine xenograft models derived from bladder cancer cell lines. 
Intraperitoneal delivery of both drugs was effective in reducing the level of DNA methylation at 
the P16 promoter. Murine tumors also exhibited a growth inhibition, although this treatment was 
insufficient to reduce the size of the tumors. A subcutaneous administration delivered similar 
results. Toxicity profile, however, was more favorable with subcutaneous injection 72. While 
zebularine effectively induced hypomethylation73 and reactivated silenced genes74 in T24 bladder 
cell lines, another study showed its’ complex metabolism and limited incorporation into the DNA 
in bladder cancer cell lines. This may be the reason for lower efficacy of zebularine compared to 
azacitidine and decitabine in bladder cancer in vitro 75. Interestingly, zebularine increased 
radiation-induced DNA damage in bladder cancer cell line and increased the radiation induced 
tumor growth delay in xenograft mouse model 76. The function of DNMT1 in bladder cancer cell 
lines was recently discovered to be mediated by the virtue of long non-coding (lnc) RNA 
DBCCR1-003 derived from the locus of DBCCR1 tumor suppressor gene 77. Habuchi et al. 
previously linked the loss of DBCCR1 expression and its association with transitional-cell bladder 
cancer 78. Qi et al. reported that DBCCR1-003 normally binds to DNMT1 and prevents the 
hypermethylation of DBCCR1 thus allowing its expression. Treatment with decitabine or 
overexpression of DBCCR1-003 resulted into increased expression of DBCCR1 via reversed 
promoter hypermethylation and DNMT1 binding to DBCCR1-003 and promoter DBCCR1 in T24 
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bladder cancer cell line.  Such process led to significant growth inhibition of the cell line 
suggesting DBCCR1-003 as novel biomarker and potential treatment target 77. In-vivo experiments 
in patient-derived bladder cancer xenografts in mice showed that guadecitabine reduced DNA 
methylation at the p16 promoter region and reduced the growth of tumors in xenografts 79.  
A combination of azacitidine with sodium phenylbutyrate was used in a phase I study of patients 
with refractory solid tumors. Two of 28 patients had bladder cancer, however, no objective 
responses were observed within this trial 80.  Another phase I study used azacitidine with valproic 
acid in 55 patients with refractory malignancies of whom 3 had advanced urothelial cancer. The 
combination did not produce any objective responses. Stable disease was achieved in 25% of 
patients with various malignancies, other than urothelial carcinoma 81.   
Two clinical trials evaluating treatment with decitabine (NCT00030615) and CC-486, oral 
formulation of azacitidine (NCT01478685) in solid tumors including bladder cancer were 
conducted, but to our best knowledge, the results were not reported yet.  Another clinical study 
(NCT02223052) with CC-486 in solid tumors including genitourinary cancer is currently 
underway. Additionally, a genomic-based assignment of treatment including azacitidine and 
decitabine is currently ongoing in advanced urothelial carcinoma (NCT02788201). 
A phase I study of antisense oligonucleotide inhibitor of DNMT1 assessed the safety and efficacy 
of MG98, given in an infusion over 7 days to 33 patients with solid tumors, including bladder, 
upper urinary tract and prostate cancer. Treatment related toxicities were generally mild and most 
common being fatigue, headache and myalgia of grade ≤ 2. Dose limiting toxicities were grade 3 
transaminitis and grade 3 thrombocytopenia. Evidence of activity was observed in this study, 
however, none of the patients that responded had genitourinary cancers 82.   
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Fluorocyclo-pentenylcytosine (RX-3117) have shown antitumor activity in gemcitabine resistant 
pre-clinical models and is currently being evaluated in a phase I/II study in pancreatic and 
urothelial cancer (NCT02030067) 46-49. 
The insufficient clinical activity of most of the DNMTis in urothelial cancer could be explained 
by the short half-life of the first generation DNMTi agents. From a mechanistic standpoint, 
DNMTis may be better used in combination with cytotoxic drugs such as cisplatin or with immune 
checkpoint inhibitors.  
 
6.3. Renal Cell Carcinoma 
Abnormal hypermethylation as well as hypomethylation of DNA may occur in renal cell 
carcinoma (RCC), resulting in activation of tumorigenesis and chromosomal instability 83, 84. 
Numerous tumor suppressor genes have been reported to be partially or completely silenced due-
to hypermethylation of their enhancer and promoters leading to increased tumor cell proliferation, 
invasion, and metastasis 85. Deep DNA methylation and transcriptome profiling of diverse 
histological RCC subtypes uncovered that clear cell (ccRCC), papillary and translocation RCC as 
well as mucionous and spindle cell carcinomas, are 3-fold more hypermethylated as compared to 
oncocytoma and chromophobe RCC 86. Moris et al. described nine genes showing frequent 
promoter region methylation in primary RCC tumor samples. The methylation of SCUBE3 was 
associated with a significantly increased risk of cancer death or relapse 87. Li et al. found that 
DNMT1 protein was expressed significantly higher in ccRCC compared to normal tissues (56.2% 
and 27.3%, respectively). The expression of DNMT1 was positively correlated with tumor size, 
highly malignant phenotype, lymph node metastasis, vascular invasion, recurrence and poor 
prognosis. This observation was confirmed in vitro in cell lines,  where knockdown of DNMT1 
significantly inhibited ccRCC cell viability, induced apoptosis, decreased colony formation and 
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the invading ability 88. German group recently proposed metastasis associated methylome 
signature obtained from genome-wide TCGA dataset. Authors predicted metastatic disease with 
93% sensitivity and 89% specificity and proposed the prospective validation of this tool 89. 
Treatment with azacitidine resulted in suppression of cell proliferation in all 15 RCC cell lines 
evaluated by Ricketts et al. Interestingly, response correlated with alterations in VHL promoter 
methylation, however some cell lines without VHL tumor suppressor gene methylation responded 
to treatment as well. This finding is suggestive of other hypermethylated suppressor genes 
activated with DNMTi treatment with several hypermethylated candidate tumor suppressor genes 
identified (RGS7, NEFM, TMEM74, GCM2 and AEBP1). Methylation of GCM2, NEFM and 
RGS7 also strongly correlated with poor prognosis 90. Treatment of A-498 RCC cell line with low-
dose zebularine resulted in limited cell inhibition, however, authors observed an up-regulation and 
down-regulation of 308 and 253 gene transcripts, respectively. Many of the re-expressed genes 
belong to metallolthionein family, potent protectors against oxidative stress, that were discovered 
to be down-regulated in RCC tumors 91. Decitabine, but not zebularine was able to reexpress a 
hypermethylated VHL gene in RCC cell lines and caused a tumor shrinkage in RCC xenograft 
mouse model. Only tumors with hypermethylated VHL gene responded to treatment. VHL 
mutated mice did not show any response 92. Guadecitabine showed an interesting potential to 
increase immunogenicity of renal cell carcinoma and other tumors cell lines. Treatment with 
guadecitabine induced a de novo expression or reexpression of cancer testis antigen related genes 
(MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A10, GAGE 1-2, GAGE 1-6, NY-ESO-1, 
and SSX 1-5) and HLA class I antigens of ICAM-1, an important factor for improved recognition 
of cancer cells by gp-100 specific cytotoxic T lymphocytes 93. 
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Reu and colleagues have shown a synergistic potential of cytokine therapy combined with 
decitabine. Resistance to the antiproliferative and apoptotic effects of interferons (IFNs) was 
postulated to result from silencing of IFN response genes by promoter hypermethylation. 
Treatment of human RCC cells with decitabine overcame IFN resistance, while normal epithelial 
kidney cells remained unaffected. IFN response gene expression was augmented greater than 10 
times by decitabine 94.  
A phase I study conducted by Lin et al. aimed to find the safe and effective dose of azacitidine in 
combination sodium phenylbutyrate in refractory solid tumors. Three of patients on this study had 
renal cell carcinoma. While clinical responses were disappointing, treatment induced undetectable 
activity of DNMTs in renal cell carcinoma patients at low doses (15mg/m2) 80.   An ongoing phase 
I/II clinical trial is assessing the feasibility, safety, and efficacy of anti-PD-1 antibody in 
combination with low-dose decitabine in patients with relapsed or refractory malignancies 
including RCC (NCT02961101). Another phase I/II trial of azacitidine in combination with 
bevacizumab for advanced RCC previously treated with VEGF- or mTOR-targeted therapy with 
or without prior immunotherapy was recently concluded and the results are pending 
(NCT00934440). 
 
6.4 Prostate Cancer 
Among all solid tumors evaluated in TCGA, prostate cancer has the lowest level of expression of 
DNMT3A/B (Figure 2). GSTP1 is, however, frequently methylated gene in prostate cancer 95. 
Functional epigenetic analyses in prostate cancer cell lines showed the reexpression of genes 
regulated by hypermethylation their promoters after treatment with zebularine or decitabine (IFI6, 
GSTP1) 95-97. While zebularine failed to achieve the reexpression of GCTP1 it effectively 
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reexpressed two GST detoxifying enzimes (GST-pi and GST-mu) in mice 96, 97. Another 
commonly hypermethylated promoter in ASC gene (apoptosis associated speck-like protein) was 
demethylated and reexpressed by decitabine and zebularine in five prostate cancer cell lines 98. 
Gertych et al. demonstrated that treatment with azacitidine and zebularine changed the DNA 
topology status in terms of DNA-histone complex decondensation, along with demethylating 
effects in prostate and liver cancer cells 99. A study by Kim et al. described that overexpression of 
lysine-specific demethylase 4A (JMJD2A) resulted in initiation of prostate cancer development in 
mice further mediated by JMJD2A/ETV1/YAP1 pathway 100. In further preclinical studies, 
azacitidine, demonstrated synergistic effects with docetaxel and cisplatin in androgen receptor 
(AR)-positive 22RV1 and in AR-negative PC3 cells 101. Decitabine also exhibited synergy with 
cisplatin and cyclophosphamide in non-prostate cancer cell lines, although the relationship to 
induced DNA demethylation was unclear 102. Prostate cancer cell lines that were treated with 
decitabine showed partial demethylation of TMS1/ASC locus (a frequently hypermethylated gene 
in prostate cancer) and the subset of alleles remained unmethylated for over 3 months while others 
were remethylated within 1 week 103. Azacitidine prevented de novo development of cancer in all 
of 14 mice used in experiments with the model of transgenic adenocarcinoma of the mouse prostate 
104. 
Azacitidine and sodium phenylbutyrate failed to induce the response in a phase I trial including 5 
prostate cancer patients, perhaps owing to the undetectable DNMT activity before the treatment 
80. Another phase I trial evaluating azacitidine and valproic acid where 2 patients with advanced 
prostate cancer were included reported stable disease in 1 patient 81. In a phase II trial, 
subcutaneous azacitidine did not resensitize tumors to androgen-deprivation therapy in 36 patients 
with progressive castration resistant prostate cancer (CRPC) 105. However, the combination of 
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azacitidine with docetaxel was active in metastatic CRPC patients 106. In a phase I/II study, 
azacitidine was given daily for 5 days followed by docetaxel on day 6. PSA response was seen in 
10 of 19 evaluable patients and objective response was observed in 3 of 10 evaluable patients. 
Significant demethylation of GADD45A was observed with azacitidine treatment 106. 
Thus far, the clinical efficacy outcomes of azacitidine in prostate cancer trials have demonstrated 
only modest activity. Possible reasons may be the low level of DNTM3 expression or instability 
of DNA methylation inhibitors due to the short half life 107. Wong et al. provided strong evidence 
for DNA methylation recovery and found that H3K9 trimethylation and H3K27 trimethylation 
were closely associated with DNA methylation recovery 108. Overall, the efficacy of DNMTi in 
prostate cancer treatment is yet to be determined 2. 
 
6.5 Penile cancer 
Several studies summarized by Kuasne et al. attempted to describe epigenetic alterations in penile 
carcinoma (PeCa). Hypermethylation of the CDK2A gene promoter was found to be present in 15 
to 42% of PeCa samples 109.  Feber et al. evaluated the methylation profile of 38 PeCa samples 
using high-density genome-wide methylation arrays. The authors identified a clear 
hypermethylation profile associated with cancer phenotype and identified novel epigenetic 
signatures associated with HPV infection and loco-regional spread. Interestingly, epigenetic 
signatures that were predictive of metastases in lymph nodes suggested a lower metastatic potential 
of hypermethylated tumors. In addition, HPV infection showed significant correlation with DNA 
methylation. The majority of HPV-positive samples were hypomethylated and showed better 
clinical outcome 110. Distinct methylome and transcriptome patterns were described in more recent 
genome-wide methylation and transcriptome analysis. Aberrant DNA methylation was linked to 
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expression of specific genes connected to higher tumor aggressiveness and shorter duration of 
survival 111. These studies suggest a role for DNA methylation in PeCa. Nevertheless, to our 
knowledge pre-clinical and clinical trials with DNMTis have not been reported. 
 
Conclusion 
Epigenetic targeting is an exciting new field in cancer research. Pre-clinical efforts to elucidate 
underlying mechanisms of treatment resistance have led to the initiation of several clinical trials 
involving epigenetic modulation in genitourinary malignancies. Current knowledge does not yet 
robustly support the immediate incorporation if DNMTis into treatment of genitourinary cancer. 
However, DNA methylation appears to be an important mechanism of treatment resistance, which 
may be overcome by incorporating DNMTis into the therapy. Initial studies evaluating older 
generations of DNMTis have shown insufficient activity due to unfavorable pharmacokinetics. 
Nevertheless, the discovery of new generation of DNMTis, coupled to a better understanding of 
mechanisms of action, have provided the rational for combination therapies, which may lead to 
more favorable clinical outcomes. Large clinical studies are needed to provide better understanding 
whether these agents will find place in everyday treatment of genitourinary cancer.  
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Table 1. Inclusion, exclusion criteria and the selection process for including publications inclusion 
in the review article  
 
Inclusion criteria Exclusion criteria 
1. Pre-clinical in vitro studies evaluating 
DNA methyltransferase inhibitors 
(DNMTis) in genitourinary (GU) 
tumors including germ-cell tumors, 
bladder cancer, renal cell carcinoma, 
prostate cancer and penile cancer. 
2. Pre-clinical in vivo studies evaluating 
DNMTis in GU tumors including germ-
cell tumors, bladder cancer, renal cell 
carcinoma, prostate cancer and penile 
cancer. 
1. Title including diagnoses, cell 
lines and animal models for 
cancers different than GU (e.g. 
hematologic malignancies, other 
solid tumors). 
2. Abstract including cell lines, 
animal models and clinical trials 
for cancers different than GU. 
3. Full text articles including cell 
lines, animal models and clinical 

























3. Clinical studies evaluating DNMTis in 
GU tumors including germ-cell tumors, 
bladder cancer, renal cell carcinoma, 
prostate cancer and penile cancer. 
 
Selection process of published works was conducted in several steps. First, review of 
publication titles retrieved from the literature search was performed. If title met the inclusion 
criteria, the abstract was reviewed. If abstract met the inclusion criteria, the full text article was 
reviewed. If inclusion criteria for full text article were met, the article was included in our review 
manuscript. If title of general nature was found (e.g. DNMTis in cancer, solid tumors etc.), the 
abstract was reviewed. Subsequently, if abstract did not clearly specify the cancer types, the full 




Abbreviations: DLBCL – diffuse large B-cell lymphoma, chRCC – chromophobe renal cell 
cancer, PCPG – pheochromocytoma and paraganglioam, ACC – adrenocortical carcinomas, 
ccRCC – clear cell renal cell carcinoma, pRCC – papillary renal cell carcinoma, AML – acute 
myeloid leukemia, GBM - glioblastoma 
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